Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 15807.1;9 PFLS-LS
• Titre du projet anglais: Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

Description succincte (Allemand)

Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

Description succincte (Anglais)

Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

Résumé des résultats (Abstract) (Allemand)

The proposed CTI project aims to develop TAFTs for the treatment of ophthalmic diseases such as retinal vascular diseases, glaucoma and age-related macula degeneration. TAFTs are a new class of biologics modulating gene expression. They are designed to target expression of specific receptor proteins connected to the pathophysiology of eye diseases. The project is expected to bring TAFTs from the preclinical to the clinical stage, thus strenghening Aliophtha's TAFT pipeline.

Résumé des résultats (Abstract) (Anglais)

The proposed CTI project aims to develop TAFTs for the treatment of ophthalmic diseases such as retinal vascular diseases, glaucoma and age-related macula degeneration. TAFTs are a new class of biologics modulating gene expression. They are designed to target expression of specific receptor proteins connected to the pathophysiology of eye diseases. The project is expected to bring TAFTs from the preclinical to the clinical stage, thus strenghening Aliophtha's TAFT pipeline.